Skip to main content

AbCellera Biologics

AbCellera Biologics Inc is a Canadian biotechnology company providing an AI-powered antibody discovery and development platform. The company searches, decodes, and analyzes natural immune systems to discover monoclonal antibody candidates for therapeutic applications. Main revenue drivers consist of research collaboration fees, milestone payments, licensing fees, and potential downstream product royalties. AbCellera serves global pharmaceutical enterprises, mid-sized biotechnology companies, and academic research institutions across North America and Europe. The company occupies a prominent market position as an technology engine for rapid therapeutic antibody discovery. Headquartered in Vancouver, Canada, AbCellera Biologics Inc is listed on the Nasdaq Stock Market.

6 of the funds FundTelligence covers report a position in AbCellera Biologics.

Legal name
AbCellera Biologics Inc
Sector
Health Care
Country
Canada
Funds holding it
6
Exposure themes
Autoimmune diseases, Biotechnology platforms, Treatment, Women's Health

Funds holding AbCellera Biologics

Loading...